Johnson & Johnson plunked down $3.4 billion in cash to acquire privately held Auris Health Inc., a company that has developed robotic endoscopic technologies for the treatment of lung cancer.
The miniature robot – the bacteria-inspired brainchild of a team of scientists in Switzerland seeking new methods to deliver drugs to diseased tissue – is designed to wend its way through blood vessels and other systems in the body.
While some manufacturing industries have long utilized automation throughout their processes and product production, the biopharma industry is comparatively behind the times.
Voice search (such as Apple Siri) and voice assistants (such as Amazon ECHO “Alexa”) are on the rise, and it’s been predicted that by the end of 2020, 50% of interactions with technology will be via “conversations” with them.
With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China.
Todd Campbell, writing for The Motley Fool, notes four biopharma stocks that topped out in the S&P 500 in 2017.
Genome BC is investing in a cancer research project that aims to speed up genetic tests of tumors through the development of a robotics system.
The world’s top medical technology companies are turning to robots to help with complex knee surgery, promising quicker procedures and better results in operations that often leave patients dissatisfied.
Japanese automakers are looking beyond the industry trend to develop self-driving cars and turning their attention to robots to help keep the country’s rapidly graying society on the move.
Kaspar the social robot has helped around 170 autistic children in a handful of schools and hospitals over the last 10 years. But with approximately 700,000 people in Britain on the autism spectrum, according to the National Autistic Society, the university wants Kaspar to help more people.